NEUVENGE Trademark

Trademark Overview

On Wednesday, June 20, 2012, a trademark application was filed for NEUVENGE with the United States Patent and Trademark Office. The USPTO has given the NEUVENGE trademark a serial number of 85657232. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 10, 2015. This trademark is owned by Dendreon Corporation. The NEUVENGE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment of cancer, infections and autoimmune diseases
neuvenge

General Information

Serial Number85657232
Word MarkNEUVENGE
Filing DateWednesday, June 20, 2012
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 10, 2015
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 13, 2012

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment of cancer, infections and autoimmune diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, June 28, 2012
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameDENDREON PHARMACEUTICALS, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressBRIDGEWATER, NJ 08807
Party NameDendreon Corporation
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeattle, WA 98101
Party NameDendreon Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeattle, WA 98121

Trademark Events

Event DateEvent Description
Monday, August 10, 2015ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, August 10, 2015ABANDONMENT - NO USE STATEMENT FILED
Wednesday, July 29, 2015ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY
Wednesday, July 15, 2015AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Wednesday, May 20, 2015ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 20, 2015TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, January 7, 2015NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 6, 2015EXTENSION 4 GRANTED
Wednesday, December 24, 2014EXTENSION 4 FILED
Wednesday, December 24, 2014TEAS EXTENSION RECEIVED
Friday, May 30, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, May 29, 2014EXTENSION 3 GRANTED
Friday, May 23, 2014EXTENSION 3 FILED
Friday, May 23, 2014TEAS EXTENSION RECEIVED
Tuesday, January 28, 2014NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 27, 2014EXTENSION 2 GRANTED
Friday, December 6, 2013EXTENSION 2 FILED
Friday, January 24, 2014CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, December 6, 2013TEAS EXTENSION RECEIVED
Wednesday, November 6, 2013TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, May 16, 2013NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 14, 2013EXTENSION 1 GRANTED
Tuesday, May 14, 2013EXTENSION 1 FILED
Tuesday, May 14, 2013TEAS EXTENSION RECEIVED
Tuesday, January 8, 2013NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, November 13, 2012OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, November 13, 2012PUBLISHED FOR OPPOSITION
Wednesday, October 24, 2012NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, October 4, 2012APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, October 4, 2012ASSIGNED TO EXAMINER
Thursday, June 28, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Saturday, June 23, 2012NEW APPLICATION ENTERED IN TRAM

Related Keywords

neuvenge autoimmune diseases infections cancer treatment pharmaceuticals